The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01071642

Enrollment

100

Registered

2010-02-19

Start date

2010-03-31

Completion date

2010-11-30

Last updated

2017-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure

Keywords

Change in eGFR from baseline to 72 hours following the exposure to the contrast., Rate of eGFR decrease>25% from the baseline, Length of hospitalization., Requirement of unplanned therapy for elevated blood pressure

Brief summary

The aim of the current study is to evaluate prospectively whether concomitant administration of RAAS blockers (namely ACE-I and ARBs') influence the change in estimated GFR (eGFR) after administration of contrast media in patients undergoing non-emergent coronary angiography.

Interventions

DRUGstop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure

ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure

DRUGACE/ARB stopped 24 hours before procedure and start immediately after

ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* 1\. Age\>18 years * 2\. Subjects on chronic therapy with ACE-I and/or ARBs' (confirmed by electronic records in their medical file) * 3\. Subjects planned to undergo non-emergent coronary angiography. * 4\. Signed informed consent

Exclusion criteria

* 1\. eGFR\<30 ml/min at baseline * 2\. Chronic utilization of NSAIDS and Cox-2 selective inhibitors * 3\. Chronic treatment with mineralocorticosteroid receptor blocker * 4\. Systolic blood pressure\<90 mmHg * 5\. Planned staged (repeated) procedure within 48 hours * 6\. Administration of contrast within 14 days prior to the enrollment * 7\. contraindication to stop ACE-I or ARB'S

Design outcomes

Primary

Measure	Time frame
Change in eGFR from baseline to 48 hours following the exposure to the contrast.	48 hours after exposure to the contrast

Secondary

Measure	Time frame
1. Rate of eGFR decrease>25% from the baseline, 2. Length of hospitalization,	48-72 hours after exposure to contrast

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026